ERAS
Erasca Inc
NASDAQ: ERAS · HEALTHCARE · BIOTECHNOLOGY
$17.72
-2.42% today
Updated 2026-07-29
Market cap
$6.63B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.92
Dividend yield
—
52W range
$1 – $24
Volume
5.4M
WallStSmart proprietary scores
25
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-0.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$22.80
+28.67%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy6 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.12x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -0.66 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-27.42M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-242.81M | $-125.04M | $-161.65M | $-124.55M | $-183.44M |
| EPS | — | — | — | — | $-0.92 |
| Free cash flow | $-119.81M | $-102.99M | $-131.98M | $-95.58M | $-27.42M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Erasca Inc trades at $17.72. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -0.66, it sits in the distress.
Frequently asked questions
What is Erasca Inc's stock price?
Erasca Inc (ERAS) trades at $17.72.
Is Erasca Inc overvalued?
Erasca Inc carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Erasca Inc (ERAS)?
The 12-month analyst consensus target is $22.80, about 28.7% above the current $17.72. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Erasca Inc's Altman Z-Score is -0.66, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-70.39%
Beta0.67
50D MA$15.19
200D MA$10.51
Shares out0.35B
Float0.25B
Short ratio—
Avg volume5.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—